Deanne E. Maynard

I'll research this attorney's background and verify the tracked matters.

Deanne E. Maynard — Morrison Foerster (Washington, D.C.)

Specialty and focus. Maynard is an appellate advocate, not a first-chair trial lawyer, and her patent work is concentrated at the Federal Circuit. Professional bios describe a technology range spanning pharmaceuticals/life sciences, software, consumer electronics, chemical and medical-device arts, and she has argued for both patentees and accused infringers. The two tracked matters are both Hatch-Waxman/ANDA pharmaceutical disputes: the fingolimod (Gilenya) litigation captioned Novartis Pharmaceuticals Corp. v. HEC Pharm Co. (D. Del., No. 1:18-cv-01043) and the parallel Federal Circuit appeal, Novartis Pharmaceuticals Corp. v. Accord Healthcare, Inc. (Fed. Cir. No. 2021-1070). She also is listed on Federal Circuit briefing in Novartis Pharmaceuticals Corp. v. MSN Pharmaceuticals, Inc. (No. 25-1927), an appeal from denial of a preliminary injunction; her life-sciences appellate docket otherwise includes Sandoz v. Amgen, Momenta v. Amphastar, and BASF v. Johnson Matthey.

Side preference. The tracked sample is small and one-sided — 2 appearances, both plaintiff/patentee side, both for Novartis — so it is not a reliable indicator of a defense or NPE practice. Third-party sources consistently characterize her as representing both patent owners and defendants on appeal, and her Federal Circuit defense work includes successfully defeating an attempt to revive a jury infringement verdict against VMware in In re Cirba (Fed. Cir. 2021). On the verified record, she is best described as a both-sides appellate specialist rather than a dedicated plaintiff-side or NPE advocate; the Novartis matters reflect the pharma patentee work that dominates her tracked appearances.

Notable results. Her most consequential tracked outcome is the Gilenya appeal. A Federal Circuit panel initially affirmed the District of Delaware's judgment that the claims of U.S. Patent No. 9,187,405 were not invalid and were infringed; after a panel rehearing in which retiring Judge O'Malley was replaced by Judge Hughes, the court reversed and held the "absent an immediately preceding loading dose regimen" limitation lacked written description support (Fed. Cir. June 21, 2022). Maynard's team sought certiorari on the written description standard and on the panel-substitution procedure (No. 22-671, Novartis v. HEC Pharm); the Supreme Court denied cert on April 17, 2023, leaving the invalidation in place. Elsewhere, she argued and won Sandoz v. Amgen (2017), a unanimous Supreme Court ruling for her client on the biosimilar notice provisions of the BPCIA — a result that drew Law360 Appellate MVP recognition — and argued MedImmune, Inc. v. Genentech, Inc. for the patentee on declaratory-judgment standing.

Firm, PTAB, and credentials. She has been at Morrison & Foerster throughout the tracked period and co-chairs its Appellate + Supreme Court practice; before joining MoFo she was an Assistant to the U.S. Solicitor General (2004–2009) and a partner at Jenner & Block in Washington, D.C. She serves as Chair of the Federal Circuit's Advisory Council. On PTAB/IPR practice: no public record of regular inter partes review or PGR appearances surfaced in this search, and her described role is appellate — she should not be pitched as a standing PTAB practitioner without further confirmation. Bar and education, as reliably sourced: District of Columbia (1991) and Virginia; J.D., Harvard Law School (1991, magna cum laude, Harvard Law Review editor); B.A., University of Virginia; clerkships with Judge Stanley S. Harris (D.D.C.), Justice Lewis F. Powell, Jr. (ret.)/Justice John Paul Stevens, and Justice Stephen G. Breyer.